Trial
NCT03851081
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Pfizer
Condition
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Intervention
Inotuzumab Ozogamicin
Why stopped
no accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-28